Figure 5

The effect of IVIg (FLEBOGAMMA) on the cytotoxicity of pooled human serum (50%) against pRBCs. (A) The cytotoxicity of pooled human serum (50%) against WT pRBCs was not inhibited by IVIg. (B) The cytotoxicity of pooled human serum (50%) against GTKO pRBCs was inhibited by high-dose IVIg (*p < 0.05). (C) There was no cytotoxicity of pooled human serum (50%) against TKO pRBCs with/without IVIg. The cytotoxicity of pooled human serum (50%) against (D) WT and (E) GTKO pAECs was significantly inhibited by high-dose (> 10 mg/ml) IVIg. See “Materials and methods” section [(A)–(C) Antibody-dependent complement-mediated hemolytic assay, and (D, E) Antibody-dependent complement-mediated cytotoxicity (CDC) of pAECs]. (A)–(C) Non-heat-inactivated serum (i.e., with complement activity) was used in the hemolytic assay. (D, E) Heat-inactivated serum + rabbit complement (i.e., exogenous complement) was used in the CDC assay of pAECs. The dotted line represents cut-off value (7%), below which cytotoxicity is considered negative. Results are expressed as mean + /− SD (*p < 0.05, **p < 0.01).